A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05613088 |
Recruitment Status :
Recruiting
First Posted : November 14, 2022
Last Update Posted : May 7, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neoplasms, Ovarian | Drug: MORAb-202 Drug: Paclitaxel Drug: Pegylated Liposomal Doxorubicin (PLD) Drug: Topotecan | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 90 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
Actual Study Start Date : | February 1, 2023 |
Estimated Primary Completion Date : | June 5, 2024 |
Estimated Study Completion Date : | October 11, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: MORAb-202 |
Drug: MORAb-202
Specified dose on specified days
Other Names:
|
Experimental: Investigator's Choice Chemotherapy |
Drug: Paclitaxel
Specified dose on specified days
Other Name: Bendalis Drug: Pegylated Liposomal Doxorubicin (PLD) Specified dose on specified days
Other Name: Caelyx Drug: Topotecan Specified dose on specified days
Other Name: Hycamtin |
- Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment [ Time Frame: Up to 2 years ]
- Proportion of participants with treatment related adverse events (TRAEs) leading to study discontinuation [ Time Frame: Up to 2 years ]
- Number of participants with adverse events (AEs) [ Time Frame: Up to 2 years ]
- Number of participants with serious adverse events (SAEs) [ Time Frame: Up to 2 years ]
- Number of participants with AEs leading to discontinuation [ Time Frame: Up to 2 years ]
- Number of participants with TRAEs [ Time Frame: Up to 2 years ]
- Number of participants with TRSAEs [ Time Frame: Up to 2 years ]
- Number of participants with AEs of special interest (AESIs) [ Time Frame: Up to 2 years ]
- Number of deaths [ Time Frame: Up to 2 years ]
- Number of participants with laboratory abnormalities [ Time Frame: Up to 2 years ]
- Disease control rate (DCR) by RECIST v1.1 per investigator assessment [ Time Frame: Up to 2 years ]
- Duration of Response (DoR) by RECIST v1.1 per investigator assessment [ Time Frame: Up to 2 years ]
- Progression-free survival (PFS) by RECIST v1.1 per investigator assessment [ Time Frame: Up to 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Female participants with histologically-confirmed diagnosis of HGS ovarian, primary peritoneal, or fallopian tube cancer.
- Platinum-resistant disease, defined as:
- For participants who had only 1 line of platinum-based therapy: progression between > 1 month and ≤ 6 months after the last dose of platinum-based therapy of at least 4 cycles.
- For participants who had 2 or 3 lines of platinum-based therapy: progression ≤ 6 months after the last dose of platinum-based therapy.
- Participants have received at least 1 but no more than 3 prior lines of systemic therapy and for whom single-agent therapy is appropriate as the next line of therapy. Participants may have been treated with up to 1 line of therapy subsequent to determination of platinum-resistance.
- Disease progression per RECIST v1.1 (by investigator assessment) of at least 1 measurable lesion on or after the most recent therapy.
- Either formalin-fixed, paraffin-embedded (FFPE) tissue (up to 5 years old) or newly-obtained biopsies must be available for FRα assessment prior to randomization.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
Exclusion Criteria:
Medical Conditions
- Clear cell, mucinous, endometrioid or sarcomatous histology, or mixed tumors containing components of any of these histologies, or low grade or borderline ovarian cancer.
- Primary platinum-refractory ovarian cancer defined as disease progression within 1 month of the last dose of the first line platinum-containing regimen.
- Pulmonary function test (PFT) abnormalities: FEV1 < 70% or FVC < 60%, and DLCO < 80%.
- Investigator-assessed current ILD/pneumonitis, or ILD/pneumonitis suspected at screening or history of ILD/pneumonitis of any severity including ILD/pneumonitis from prior anti-cancer therapy.
- Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage.
Physical and Laboratory Test Findings
- Evidence of organ dysfunction or any clinically-significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory determinations beyond what is consistent with the target population.
Allergies and Adverse Drug Reactions
- Has any prior severe hypersensitivity (≥ Grade 3) to monoclonal antibodies or eribulin or contraindication to the receipt of corticosteroids or any of the excipients (investigators should refer to the prescribing information for the selected corticosteroid).
- History of allergy or contraindication to IC chemotherapy agent selected if randomized to Arm C.
Other protocol-defined inclusion/exclusion criteria apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05613088
Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com | 855-907-3286 | Clinical.Trials@bms.com | |
Contact: First line of the email MUST contain the NCT# and Site #. |
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Responsible Party: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT05613088 |
Other Study ID Numbers: |
CA116-001 2021-004807-42 ( EudraCT Number ) |
First Posted: | November 14, 2022 Key Record Dates |
Last Update Posted: | May 7, 2024 |
Last Verified: | May 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) |
Time Frame: | See plan description |
Access Criteria: | See plan description |
URL: | https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Platinum-resistant ovarian cancer (PROC) Primary peritoneal cancer Fallopian tube cancer MORAb-202 Folate-receptor alpha |
ADC Antibody-drug conjugate Epithelial ovarian cancer High grade serous Farletuzumab ecteribulin |
Fallopian Tube Neoplasms Ovarian Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Fallopian Tube Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Diseases Endocrine Gland Neoplasms Ovarian Diseases |
Endocrine System Diseases Gonadal Disorders Paclitaxel Doxorubicin Liposomal doxorubicin Topotecan Farletuzumab Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antibiotics, Antineoplastic Topoisomerase II Inhibitors |